Company / Free Cash Flow
Arbutus Biopharma Corp Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$39.6M
FY2025
5-year range
-$86.9M / -$35.9M
FY2021-FY2025
Trend
+39.1%
vs FY2024
Sector context
#76 of 194
Health Care
What the data says
At -$40M, Arbutus Biopharma Corp's free cash flow ranks #76 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$87M in FY2023 to -$36M in FY2022.
Based on SEC 10-K filings.
-$40M in FY2025.
Improved from -$87M to -$40M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#76 of 194 in Health CareTop 39% of 194This company -$39.6M Sector average $470.6M
▼
-108.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 39.1% year-over-year.
- Ranks #76 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$39.6M | +39.1% |
| FY2024 | -$65.0M | +25.2% |
| FY2023 | -$86.9M | -142.4% |
| FY2022 | -$35.9M | +47.5% |
| FY2021 | -$68.3M | +4.5% |
| FY2020 | -$71.6M | -3.8% |
| FY2019 | -$69.0M | -23.4% |
| FY2018 | -$55.9M | +0.0% |
| FY2017 | -$55.9M | +9.7% |
| FY2016 | -$61.9M | -5.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026